`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MASSACHUSETTS
`
`TEVA PHARMACEUTICALS
`INTERNATIONAL GMBH and
`TEVA PHARMACEUTICALS
`USA, INC.,
`
`Plaintiffs,
`
`v.
`
`ELI LILLY AND COMPANY,
`
`Defendant.
`
`Civil Action No.
`1:18-cv-12029-ADB
`
`STIPULATION AND ORDER REGARDING ASSERTED CLAIMS
`
`Plaintiffs Teva Pharmaceuticals International GmbH; and Teva Pharmaceuticals USA, Inc.
`
`(collectively, “Plaintiffs” or “Teva”) and Defendant Eli Lilly and Company (“Lilly”) (collectively,
`
`the “Parties”) have agreed to enter into this stipulation to streamline the issues in dispute in this
`
`matter, subject to the approval of the Court;
`
`WHEREAS, Teva has asserted claims 1, 3–4, 8–9, 12, 15–16, 24, 27, and 30–31 of U.S.
`
`Patent No. 8,586,045 (the “’045 patent”); claims 1, 4–7, 15, and 17 of U.S. Patent No. 9,884,907
`
`(the “’907 patent”); and claims 1, 4–7, 15, and 17 of U.S. Patent No. 9,884,908 (the “’908 patent”)
`
`against Lilly; and
`
`WHEREAS the Parties seek to reduce the number of claims and defenses to streamline the
`
`issues for trial, and accordingly hereby agree to dismiss certain claims and certain corresponding
`
`counterclaims and defenses.
`
`NOW THEREFORE, IT IS HEREBY STIPULATED AND AGREED, by and between
`
`the Parties hereto, and subject to the approval of the Court, as follows:
`
`
`
`Case 1:18-cv-12029-ADB Document 287 Filed 03/28/22 Page 2 of 5
`
`1.
`
`Teva stipulates that it voluntarily dismisses its claims of infringement against Lilly
`
`of claims 1, 3–4, 8–9, 12, 15–16 and 31 of the ’045 patent, claim 7 of the ’907 patent, and claim 7
`
`of the ’908 patent pertaining to Lilly’s Emgality® (galcanezumab-gnlm) product with prejudice
`
`pursuant to Fed. R. Civ. P. 41(a)(2).
`
`2.
`
`Lilly stipulates that it voluntarily dismisses its defenses and counterclaims of
`
`invalidity and non-infringement pertaining to claims 1, 3-4, 8–9, 12, 15–16 and 31 of the ’045
`
`patent, claim 7 of the ’907 patent, and claim 7 of the ’908 patent with prejudice pursuant to Fed.
`
`R. Civ. P. 41(a)(2).1
`
`3.
`
`The Parties stipulate that they will continue to assert their respective claims (see
`
`Dkt. No. 1, Counts I, VI, VII, X, XV, and XVI), counterclaims (see Dkt. No. 277, Counterclaim
`
`Counts I, II, XI–XIV, and XIX–XXI), and defenses (see Dkt. No. 277, Defenses 1, 2, 11–14, 19–
`
`25) with respect to only claims 17, 18, 19, 20, 21, 24, 27, and 30 of the ’045 patent, claims 1, 4, 5,
`
`6, 15, and 17 of the ’907 patent, and claims 1, 4, 5, 6, 15, and 17 of the ’908 patent.
`
`
`
`
`
`
`1 For the avoidance of doubt, affirmative defenses and counterclaims of unclean hands and
`inequitable conduct apply to entire patents, not specific claims.
`
`2
`
`
`
`Case 1:18-cv-12029-ADB Document 287 Filed 03/28/22 Page 3 of 5
`
`IT IS SO STIPULATED:
`
`Dated: March 28, 2022
`
`Andrea Martin (with permission)
`/s/
`Andrea L. Martin (BBO# 666117)
`BURNS & LEVINSON LLP
`125 High Street
`Boston, MA 02110-1624
`(617) 345-3000
`amartin@burnslev.com
`
`Emily R. Gabranski
`Marta Garcia Daneshvar
`Lulu Wang
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`2 Seaport Lane
`Boston, MA 02210-2001
`Emily.Gabranski@finnegan.com
`Marta.Garcia@finnegan.com
`Lulu.Wang@finnegan.com
`
`Mark J. Stewart
`Sanjay M. Jivraj
`ELI LILLY AND COMPANY
`Lilly Corporate Center
`Indianapolis, IN 46285
`stewart_mark@lilly.com
`sjivraj@lilly.com
`
`Charles E. Lipsey
`Ryan P. O’Quinn
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`1875 Explorer Street
`Suite 800
`Reston, VA 20190-6023
`Charles.Lipsey@finnegan.com
`oquinnr@finnegan.com
`
`William B. Raich
`Danielle A. Duszczyszyn
`Denise Main
`Pier D. DeRoo
`Matthew J. Luneack
`
`
`
`
`
`/s/ _Elaine Herrmann Blais__
`Douglas J. Kline (BBO# 556680)
`Elaine Herrmann Blais (BBO# 656142)
`Robert Frederickson III (BBO# 670111)
`Joshua S. Weinger (BBO# 690814)
`Alexandra Lu (BBO# 691114)
`Eric T. Romeo (BBO# 691591)
`Kathleen A. McGuinness (BBO# 693760)
`Shaobo Zhu (BBO# 697669)
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02210
`Tel.: (617) 570-1000
`Fax: (617) 523-1231
`dkline@goodwinlaw.com
`eblais@goodwinlaw.com
`rfrederickson@goodwinlaw.com
`jweinger@goodwinlaw.com
`alu@goodwinlaw.com
`eromeo@goodwinlaw.com
`kmcguinness@goodwinlaw.com
`szhu@goodwinlaw.com
`
`I. Neel Chatterjee (pro hac vice)
`GOODWIN PROCTER LLP
`601 Marshall St.
`Redwood City, CA 94063
`Tel.: (650) 752-3100
`Fax: (650) 853-1038
`nchatterjee@goodwinlaw.com
`
`Natasha Daughtrey (pro hac vice)
`GOODWIN PROCTER LLP
`601 S. Figueroa St.
`Los Angeles, CA 90017
`Tel.: (213) 426-2500
`Fax: (213) 623-1673
`ndaughtrey@goodwinlaw.com
`
`Attorneys for Plaintiffs
`
`
`3
`
`
`
`Case 1:18-cv-12029-ADB Document 287 Filed 03/28/22 Page 4 of 5
`
`Yoonjin Lee
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`William.Raich@finnegan.com
`Danielle.Duszczyszyn@finnegan.com
`Denise.Main@finnegan.com
`Pier.Deroo@finnegan.com
`Matthew.Luneack@finnegan.com
`Yoonjin.Lee@finnegan.com
`
`Attorneys for Defendant
`
`
`
`
`
`
`4
`
`
`
`Case 1:18-cv-12029-ADB Document 287 Filed 03/28/22 Page 5 of 5
`
`IT IS SO ORDERED.
`
`(cid:22)(cid:18)(cid:21)(cid:27)(cid:18)(cid:21)(cid:19)(cid:21)(cid:21)
`Dated:_________________
`
`____________________________
`Hon. Allison D. Burroughs
`United States District Judge
`
`5
`
`